{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:07:30Z","timestamp":1771600050559,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017412","name":"BD","doi-asserted-by":"publisher","award":["AABP6774"],"award-info":[{"award-number":["AABP6774"]}],"id":[{"id":"10.13039\/100017412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12629-8","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:56:44Z","timestamp":1769687804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rates and risk factors of monoresistance against isoniazid and multidrug-resistant tuberculosis in Almaty, Kazakhstan"],"prefix":"10.1186","volume":"26","author":[{"given":"Juliana G. E.","family":"Bartels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurlan","family":"Takenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyailya","family":"Chingissova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anar","family":"Rakisheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainur","family":"Eleusizova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venera","family":"Bismilda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyazzat","family":"Yeraliyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanis","family":"Ben Amor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"1","key":"12629_CR1","doi-asserted-by":"publisher","first-page":"e1003023","DOI":"10.1371\/journal.pmed.1003023","volume":"17","author":"G Sulis","year":"2020","unstructured":"Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med. 2020;17(1):e1003023.","journal-title":"PLoS Med"},{"issue":"3","key":"12629_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/ng.3767","volume":"49","author":"AL Manson","year":"2017","unstructured":"Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017;49(3):395\u2013402.","journal-title":"Nat Genet"},{"key":"12629_CR3","doi-asserted-by":"crossref","unstructured":"Cohen KA, Abeel T, McGuire AM, Desjardins CA, Munsamy V, Shea TP, et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from Kwazulu-Natal. PLoS Med. 2015;29(9):e1001880.","DOI":"10.1371\/journal.pmed.1001880"},{"key":"12629_CR4","volume-title":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update","author":"WHO","year":"2021","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021."},{"key":"12629_CR5","volume-title":"Global tuberculosis report 2023","author":"WHO","year":"2023","unstructured":"WHO. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"key":"12629_CR6","volume-title":"WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin resistant TB (MDR\/RR-TB), 2021\u20132025: background document","author":"WHO","year":"2021","unstructured":"WHO. WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin resistant TB (MDR\/RR-TB), 2021\u20132025: background document. Geneva: World Health Organization; 2021."},{"issue":"2","key":"12629_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1473-3099(19)30568-7","volume":"20","author":"A Dadu","year":"2020","unstructured":"Dadu A, Hovhannesyan A, Ahmedov S, van der Werf MJ, Dara M. Drug-resistant tuberculosis in Eastern Europe and central asia: a time-series analysis of routine surveillance data. Lancet Infect Dis. 2020;20(2):250\u20138.","journal-title":"Lancet Infect Dis"},{"key":"12629_CR8","unstructured":"WHO. Tuberculosis profile: Kazakhstan [Internet]. 2024. Available from: https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_%26entity_type=%22country%2522%26iso2=%2522KZ%2522%26lan=%2522EN%2522. Cited 9 May 2024."},{"issue":"7","key":"12629_CR9","doi-asserted-by":"publisher","first-page":"e22927","DOI":"10.1371\/journal.pone.0022927","volume":"6","author":"HE Jenkins","year":"2011","unstructured":"Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of Isoniazid resistant tuberculosis, 1994\u20132009. PLoS ONE. 2011;6(7):e22927.","journal-title":"PLoS ONE"},{"key":"12629_CR10","doi-asserted-by":"crossref","unstructured":"Bartels JGE, Takenov N, Chingissova L, Rakisheva A, Eleusizova A, Bismilda V, et al. Comparative analysis of 2 diagnostic devices for detection of Mycobacterium tuberculosis and drug resistance in Almaty, Kazakhstan, to determine the optimal diagnostic for local needs. Open Forum Infect Dis. 2025;12(7):ofaf342.","DOI":"10.1093\/ofid\/ofaf342"},{"key":"12629_CR11","unstructured":"Robinson D, Hayes A. Couch [aut S, cre, Software P, PBC, broom: Convert Statistical Objects into Tidy Tibbles [Internet]. 2024. Available from: https:\/\/cran.r-project.org\/web\/packages\/broom\/index.html. Cited 19 Nov 2024."},{"key":"12629_CR12","doi-asserted-by":"crossref","unstructured":"Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016 Sept;15(11):1081\u20139.","DOI":"10.1056\/NEJMsr1512438"},{"issue":"1","key":"12629_CR13","doi-asserted-by":"publisher","first-page":"e1003008","DOI":"10.1371\/journal.pmed.1003008","volume":"17","author":"AS Dean","year":"2020","unstructured":"Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of Isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008.","journal-title":"PLoS Med"},{"key":"12629_CR14","volume-title":"The end TB strategy","author":"WHO","year":"2015","unstructured":"WHO. The end TB strategy. Geneva: World Health Organization; 2015."},{"key":"12629_CR15","doi-asserted-by":"crossref","unstructured":"Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and\/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150.","DOI":"10.1371\/journal.pmed.1000150"},{"issue":"3","key":"12629_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1513\/AnnalsATS.201711-885ED","volume":"15","author":"M O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell M. Isoniazid monoresistance: A precursor to Multidrug-Resistant tuberculosis? Ann Am Thorac Soc. 2018;15(3):306\u20137.","journal-title":"Ann Am Thorac Soc"},{"key":"12629_CR17","volume-title":"WHO treatment guidelines for isoniazid-resistant tuberculosis","author":"WHO","year":"2018","unstructured":"WHO. WHO treatment guidelines for isoniazid-resistant tuberculosis. Geneva: World Health Organization; 2018."},{"issue":"4","key":"12629_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","volume":"6","author":"F Fregonese","year":"2018","unstructured":"Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265\u201375.","journal-title":"Lancet Respir Med"},{"key":"12629_CR19","doi-asserted-by":"crossref","unstructured":"Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, Van Gemert W, Hoffmann H et al. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill [Internet]. 2013 Oct 17;18(42). Available from: https:\/\/www.eurosurveillance.org\/content\/.","DOI":"10.2807\/1560-7917.ES2013.18.42.20609"},{"issue":"2","key":"12629_CR20","first-page":"170","volume":"9","author":"P Dewan","year":"2005","unstructured":"Dewan P, Sosnovskaja A, Thomsen V, Cicenaite J, Laserson K, Johansen I, et al. High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002. Int J Tuberc Lung Dis. 2005;9(2):170\u20134.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12629_CR21","doi-asserted-by":"crossref","unstructured":"Pardini M, Niemann S, Varaine F, Iona E, Meacci F, Orr\u00f9 G et al. Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. Tuberculosis (Edinb). 2009;89(4):317\u201324.","DOI":"10.1016\/j.tube.2009.04.002"},{"issue":"Suppl 2","key":"12629_CR22","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.5588\/pha.14.0049","volume":"4","author":"N Alikhanova","year":"2014","unstructured":"Alikhanova N, Akhundova I, Seyfaddinova M, Mammadbayov E, Mirtskulava V, R\u00fcsch-Gerdes S, et al. First National survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action. 2014;4(Suppl 2):S17\u201323.","journal-title":"Public Health Action"},{"issue":"5","key":"12629_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3201\/eid1005.030718","volume":"10","author":"HS Cox","year":"2004","unstructured":"Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I, et al. Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis. 2004;10(5):865\u201372.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"12629_CR24","doi-asserted-by":"publisher","first-page":"e074208","DOI":"10.1136\/bmjopen-2023-074208","volume":"13","author":"Y Sakko","year":"2023","unstructured":"Sakko Y, Madikenova M, Kim A, Syssoyev D, Mussina K, Gusmanov A, et al. Epidemiology of tuberculosis in kazakhstan: data from the unified National electronic healthcare system 2014\u20132019. BMJ Open. 2023;13(10):e074208.","journal-title":"BMJ Open"},{"issue":"1","key":"12629_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5588\/ijtld.15.0838","volume":"21","author":"A Davis","year":"2017","unstructured":"Davis A, Terlikbayeva A, Aifah A, Hermosilla S, Zhumadilov Z, Berikova E, et al. Risks for tuberculosis in kazakhstan: implications for prevention. Int J Tuberc Lung Dis. 2017;21(1):86\u201392.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12629_CR26","doi-asserted-by":"publisher","first-page":"1340673","DOI":"10.3389\/fpubh.2024.1340673","volume":"12","author":"D Yerezhepov","year":"2024","unstructured":"Yerezhepov D, Gabdulkayum A, Akhmetova A, Kozhamkulov U, Rakhimova S, Kairov U, et al. Pulmonary tuberculosis epidemiology and genetics in Kazakhstan. Front Public Health. 2024;12:1340673.","journal-title":"Front Public Health"},{"issue":"2","key":"12629_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1590\/s1806-37562017000000443","volume":"44","author":"DR Silva","year":"2018","unstructured":"Silva DR, Mu\u00f1oz-Torrico M, Duarte R, Galv\u00e3o T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018;44(2):145\u201352.","journal-title":"J Bras Pneumol"},{"key":"12629_CR28","doi-asserted-by":"crossref","unstructured":"Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;6(9):e1002119.","DOI":"10.1371\/journal.pmed.1002119"},{"key":"12629_CR29","first-page":"215059","volume":"2014","author":"L Krishnan","year":"2014","unstructured":"Krishnan L, Akande T, Shankar AV, McIntire KN, Gounder CR, Gupta A, et al. Gender-related barriers and delays in accessing tuberculosis diagnostic and treatment services: a systematic review of qualitative studies. Tuberc Res Treat. 2014;2014:215059.","journal-title":"Tuberc Res Treat"},{"key":"12629_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","volume":"45","author":"AN Unissa","year":"2016","unstructured":"Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of Isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016;45:474\u201392.","journal-title":"Infect Genet Evol"},{"key":"12629_CR31","doi-asserted-by":"crossref","unstructured":"Bogiel T, Dolska E, Zimna M, Nakonowska K, Krawiecka D, \u017bebracka R, et al. The usefulness of the BD MAX MDR-TB molecular test in the rapid diagnosis of multidrug-resistant tuberculosis. Pathogens. 2025;14(6):602.","DOI":"10.3390\/pathogens14060602"},{"issue":"5","key":"12629_CR32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/cid\/ciz932","volume":"71","author":"M Shah","year":"2020","unstructured":"Shah M, Paradis S, Betz J, Beylis N, Bharadwaj R, Caceres T, et al. Multicenter study of the accuracy of the BD MAX Multidrug-resistant tuberculosis assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to Rifampin and Isoniazid. Clin Infect Dis. 2020;71(5):1161\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12629_CR33","doi-asserted-by":"publisher","first-page":"e0284545","DOI":"10.1371\/journal.pone.0284545","volume":"18","author":"A Katamba","year":"2023","unstructured":"Katamba A, Ssengooba W, Sserubiri J, Semugenze D, Kasule GW, Nyombi A, et al. Evaluation of Xpert MTB\/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda. PLoS ONE. 2023;18(8):e0284545.","journal-title":"PLoS ONE"},{"issue":"3","key":"12629_CR34","doi-asserted-by":"publisher","first-page":"e0174373","DOI":"10.1371\/journal.pone.0174373","volume":"12","author":"M Droznin","year":"2017","unstructured":"Droznin M, Johnson A, Johnson AM. Multidrug resistant tuberculosis in prisons located in former Soviet countries: a systematic review. PLoS ONE. 2017;12(3):e0174373.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12629-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12629-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12629-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:16:25Z","timestamp":1771596985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12629-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12629"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12629-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved as human subjects research by Columbia University Institutional Review Board with protocol number IRB-AAAS5110 and the NSCP Ethics Committee (approval of 6 February 2020, and extension of 7 July 2021). The manufacturer, BD, had no role in the collection or analysis of the data. Participants were enrolled after providing written informed consent in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}